People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Jounce Therapeutics, Inc. | — | Biotechnology | Series C | $91.0M | $1.3B | 2020 |
Perry G. Karsen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Perry G. Karsen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Richard Murray | 1 | 5 |
| Cary G. Pfeffer | 1 | 3 |
| Kim C. Drapkin | 1 | 3 |
| Kimberlee C. Drapkin | 1 | 2 |
| Elizabeth G. Trehu | 1 | 2 |
| Robert G. Kamen | 1 | 1 |
| Robert G. Tepper | 1 | 1 |
| Luis A. G. Diaz, Jr. | 1 | 1 |
| Duncan G. Higgons | 1 | 1 |
| Robert G. Iannone | 1 | 1 |
| Barbara G. Duncan | 1 | 1 |
| Hugh M. Cole | 1 | 1 |
| Anna L. Barry | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.